Spots Global Cancer Trial Database for Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Official Title: A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Study ID: NCT02953509
Conditions
Study Description
Brief Summary: The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama At Birmingham (Uab), Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Center, Stanford, California, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
National Institutes of Health Clinical Center/ National Cancer Institute, Bethesda, Maryland, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States
Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
The Sarah Cannon Research Institute, Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Princess Alexandra Hospital, Brisbane, Queensland, Australia
St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
The Churchill Hospital, Oxford, , United Kingdom
Contact Details
Name: Gilead Study Director
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
